A Study to Evaluate the Efficacy of Androxal in Improving Glycemic Control in Men With Secondary Hypogonadism or Adult-onset Idiopathic Hypogonadotropic Hypogonadism (AIHH) and Type 2 Diabetes Mellitus With Sub-Optimum Treatment
Latest Information Update: 08 Nov 2021
Price :
$35 *
At a glance
- Drugs Enclomifene (Primary)
- Indications Hypogonadism; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Repros Therapeutics
- 10 Apr 2013 Results reporting changes in hormone levels, including changes in insulin-like growth factor-1 levels, presented at the 104th Annual Meeting of the American Association for Cancer Research.
- 10 Apr 2013 Repros Therapeutics was issued a patent for Androxal for the treatment of type 2 diabetes mellitus based on findings from this trial, according to a media release.
- 01 Dec 2011 Status changed from active, no longer recruiting to completed.